Diego Díaz García ASCO

Diego Díaz García Shares OptiTROP-Lung03 Trial Results at ASCO

Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:

“OptiTROP-Lung03 ASCO

Sac-TMT shows superior efficacy vs docetaxel in pretreated EGFRm NSCLC:

  • ORR 45.1% vs 15.6% (p=0.0004).
  • PFS: 6.9 vs 2.8 mo (HR 0.30).
  • OS: HR 0.49 (adjusted HR 0.36).
  • Better safety profile.
  • A potential new standard of care.”

Diego Díaz García Shares OptiTROP-Lung03 Trial Results at ASCO

More posts featuring Diego Díaz García.

ASCO cancer Diego Díaz García Lung cancer NSCLC OncoDaily Oncology OptiTROP-Lung03 Trial